<DOC>
	<DOCNO>NCT02842619</DOCNO>
	<brief_summary>The purpose clinical study evaluate safety efficacy BonoFill-II bone filler contain patient 's ( autologous ) adipose ( fat ) tissue-derived cell reconstruct bone two clinical indication : 1 . Bone augmentation ( e.g . sinus augmentation ) 2 . Bone graft removal cyst jaw</brief_summary>
	<brief_title>Filling Bone Defects/Voids With Autologous BonoFill-II Maxillofacial Bone Regeneration</brief_title>
	<detailed_description>Primary endpoint : The transplantation BonoFill-II maxillary mandible defect/void safe follow condition : No chronic bone infection ( Osteomyelitis ) ; significant change complete blood count ( CBC ) general health . Secondary endpoint : The transplantation BonoFill-II maxillary mandible void efficient follow condition : Following BonoFill-II implantation , bone regeneration operate site significantly accelerate . Also , bone defects/voids fill significant amount bone tissue .</detailed_description>
	<criteria>GENERAL 1 . Subject general good health opinion investigator determine medical history , vital sign physical examination safety lab test 2 . Subject rehabilitation dentist rehabilitation program 3 . Up date panoramic XRay/CT 4 . Subject able read understand inform consent form 5 . Subject provide write informed consent participate study , understand study procedure agree follow procedure 6 . Subject good oral hygiene condition per investigator 's discretion 7 . Subject participate another clinical study SINUS AUGMENTATION 1 . The subject require sinus augmentation per investigator 's discretion 2 . Healthy condition Maxillary Sinuses Oral Mucosa determine Xray BONE GRAFTING AFTER REMOVAL OF CYSTS FROM JAWS 1 . The subject require sinus augmentation per investigator 's discretion 2 . Limited cyst diagnose radicular cyst residual cyst congenital cyst developmental acquire cyst 3 . Subject refer oral &amp; maxillofacial Department removal cyst diagnosis cyst type 4 . Healthy bone determine Xray 1 . Subject record medical history disease diabetes mellitus , heart disease , renal failure , osteoporosis 2 . Subject treated systemic steroid 3 . Subject know autoimmune disease , Addison 's disease , celiac disease sprue ( glutensensitive enteropathy ) , dermatomyositis , Graves disease , Hashimoto 's thyroiditis , MS , myasthenia gravis , pernicious anemia , reactive arthritis , rheumatoid arthritis , Sjogren syndrome , systemic lupus erythematosus , Type I diabetes 4 . Subject vitiligo know scar heal problem ( keloid formation ) 5 . Subject treated anticoagulation medication ( Coumadin , Plavix similar medication ) 6 . Subject treated Oral Bisphosphonate drug ( Fosalan similar medication ) 7 . Subjects underwent chemotherapy radiotherapy 12 month prior Visit 1 8 . In case sinus augmentation unhealthy condition Maxillary Sinuses 9 . Subject current active infection illness 10 . Subject participate another clinical trial 30 day prior study period 11 . Subject pregnant lactate woman . Pregnancy verify urine test screen 12 . Subject known history significant medical disorder , investigator 's discretion contraindicate subject 's participation 13 . Subject know allergy anesthesia 14 . Positive serology either HIV , hepatitis B hepatitis C 15 . Abnormal clinically significant laboratory test exam finding per investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>